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Introduction
The ER is a fundamental eukaryotic organelle where proteins 
are made and where stringent quality-control systems operate to 
ensure that only correctly folded and properly assembled pro-
tein complexes are allowed to exit the organelle for delivery to 
their intended sites of function (Ellgaard et al., 1999; Kostova 
and Wolf, 2003; Hebert and Molinari, 2007). The mechanisms 
by which the ER operates to monitor and dispose of misfolded 
and misassembled protein complexes are beginning to be under-
stood. One mechanism is ER-associated protein degradation 
(ERAD), a regulated process by which proteins in the ER are 
exported to the cytoplasm for destruction by the proteasome 
(Kanehara et al., 2007; Vembar and Brodsky, 2008; Hirsch et al.,   
2009). Inefficient clearance of misfolded and misassembled 
proteins from the ER leads to ER stress, which results in the   
activation of a signaling cascade called the unfolded protein 
response (UPR; Schröder and Kaufman, 2005; Malhotra and 
Kaufman, 2007; Ron and Walter, 2007). In mammals, UPR is 
regulated by three main sensors called IRE1, PERK, and ATF6, 
each of which triggers, via distinct mechanisms, a coordinated 
intracellular response designed to restore protein homeostasis 
in the ER. If, however, ER stress is not alleviated, a terminal cell 
death program is then executed.
There is growing evidence that disturbances in ERAD are 
involved in human disease. For example, several diseases ap-
pear to result from mutations in proteins that cause them to mis-
fold in the ER during synthesis, where they are retained and 
eliminated by ERAD (Schröder and Kaufman, 2005; Zhao and 
Ackerman, 2006; Brodsky, 2007). Although in this scenario, 
ERAD is detrimental and leads to disease, under normal cir-
cumstances, it presumably functions as a safety mechanism to 
remove damaged and misassembled proteins before they accu-
mulate to toxic levels. However, inefficient ERAD has also been 
linked to disease. For example, mutant proteins involved in 
Huntington’s disease and amyotrophic lateral sclerosis were   
recently shown to induce ER stress by interfering with ERAD 
(Nishitoh et al., 2008; Duennwald and Lindquist, 2008).
Our knowledge of proteins involved in ERAD is expand-
ing (for reviews see Kanehara et al., 2007; Vembar and Brodsky, 
2008; Hirsch et al., 2009). Derlin proteins are thought to form 
U
nwanted  proteins  in  the  endoplasmic  reticu-
lum  (ER)  are  exported  into  the  cytoplasm  and 
degraded  by  the  proteasome  through  the  ER- 
associated protein degradation pathway (ERAD). Distur-
bances in ERAD are linked to ER stress, which has been 
implicated in the pathogenesis of several human diseases. 
However,  the  composition  and  organization  of  ERAD 
complexes in human cells is still poorly understood. In this 
paper, we describe a trimeric complex that we propose 
functions in ERAD. Knockdown of erasin, a platform for 
p97/VCP and ubiquilin binding, or knockdown of ubiq-
uilin in human cells slowed degradation of two classical 
ERAD  substrates.  In  Caenorhabditis  elegans,  ubiquilin 
and erasin are ER stress-response genes that are regu-
lated by the ire-1 branch of the unfolded protein response 
pathway. Loss of ubiquilin or erasin resulted in activation 
of ER stress, increased accumulation of polyubiquitinated 
proteins, and shortened lifespan in worms. Our results 
strongly support a role for this complex in ERAD and in 
the regulation of ER stress.
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bind radiolabeled erasin protein (Fig. 1 C). Fusion proteins con-
taining  the  central  domain  of  ubiquilin-1  bound  erasin  effi-
ciently, whereas those that lacked the domain failed to bind 
erasin (Fig. 1 C).
By  additional  pull-down  experiments  and  systematic   
N-  and  C-terminal  deletion  of  the  erasin  polypeptide,  we 
mapped the ubiquilin-1–binding site to the N-terminal end of 
erasin (between amino acids 1 and 200; see Fig. S1), which is 
distinct from the p97/VCP-binding site located at the ubiquitin 
regulatory X (UBX) domain (amino acids 316–395) of the pro-
tein (Liang et al., 2006).
Interaction between erasin and other 
ubiquitin–proteasome shuttle factors
We next investigated, using similar pull-down assays, whether 
erasin  binds  hHR23A,  another  ubiquitin–proteasome  shuttle 
protein, which like ubiquilin contains both UBL and UBA do-
mains (Elsasser and Finley, 2005; Raasi and Wolf, 2007). As 
shown in Fig. 1 (D and E), erasin-His was efficiently pulled 
down by GST-ubiquilin but not by GST-hHR23A or GST-His. 
These data suggest that erasin binds selectively to ubiquilin-1 
and not to all ubiquitin–proteasome shuttle factors.
Recombinant erasin, ubiquilin,  
and p97/VCP proteins bind together  
in a single complex
Given that erasin binds p97/VCP (Liang et al., 2006; Alexandru 
et al., 2008), we next examined whether recombinant erasin, 
ubiquilin, and p97/VCP proteins bind together in one complex. 
In these experiments, purified GST-ubiquilin or GST-His pro-
tein alone, which served as a control for nonspecific binding, 
were  mixed  with  purified  p97/VCP-His,  erasin-His,  or  both   
p97/VCP-His and erasin-His proteins, and then the GST proteins 
were affinity purified. The purified complexes were examined 
by immunoblotting for recovery of the added His-tagged pro-
teins (Fig. 1 F). The blots show that erasin-His bound strongly 
to GST-ubiquilin but not to GST alone. Also, p97/VCP-His was 
isolated in a complex with GST-ubiquilin, but only after addi-
tion of erasin-His. These results strongly suggest that p97/VCP 
binds ubiquilin through erasin and that all three proteins coexist 
in a single complex. Quantification of the stoichiometry of the 
complex suggests that erasin-His and p97/VCP-His bind GST-
ubiquilin in an 1:1 ratio (see Fig. S2). Because p97/VCP self-
assembles to form a homohexamer, it is likely that in these in 
vitro binding assays, erasin has saturated each of the six UBX-
binding  sites  of  the  p97/VCP  hexamer  (Meyer  et  al.,  2000; 
Dreveny et al., 2004).
Erasin, ubiquilin, and p97/VCP 
coimmunoprecipitate with each other  
in cells
To determine if erasin, ubiquilin, and p97/VCP form a complex 
in  cells,  we  immunoprecipitated  each  of  the  proteins  from 
HEK293 cells and found that the other two proteins were indeed 
coimmunoprecipitated (Fig. 2 A, lane 2; and Fig. 2 B, lanes 3 
and 5). The specificity of these immunoprecipitations is illus-
trated by the failure to detect any of the proteins in parallel 
the portal in the ER through which misfolded and misassembled   
proteins are exported. p97 (valosin-containing protein: p97/VCP)   
provides the main driving force for extraction of the ERAD sub-
strate (Lilley and Ploegh 2004; Ye et al., 2004). p97/VCP is re-
cruited to the ER for ERAD by binding to ER-localized proteins, 
candidates of which are gp78, derlin, VIMP, ubx2, Hrd1, erasin, 
and UBXD8. During extraction, the misfolded protein is tagged 
with a polyubiquitin chain by ubiquitin ligases (Kostova et al.,   
2007); the polyubiquitin chain serves as a signal for the recogni-
tion and destruction of the protein by the proteasome. At least five 
ER resident ubiquitin ligases—Hrd1/Der3, gp78, Doa10/Teb4, 
RMA1, and RFP2—conduct this modification, although oth-
ers probably exist. The length of the ubiquitin chain that is 
tagged onto substrates is regulated by Ufd2, which is recruited 
to the ERAD complex by binding to p97/VCP (Richly et al., 
2005). Ufd2, in turn, binds two additional factors, Rad23 and 
Dsk2, both of which contain ubiquitin-associated (UBA) and 
ubiquitin-like (UBL) domains, which appear to function in the 
transfer of the ubiquitinated substrate to the proteasome for deg-
radation (Richly et al., 2005; Elsasser and Finley, 2005). The 
UBA domains of Rad23 and Dsk2 bind polyubiquitin chains, 
and their UBL domains bind the proteasome, thus positioning 
these ubiquitin–proteasome shuttle proteins as the terminal fac-
tors that deliver the substrate to the proteasome for degradation 
(Verma et al., 2004; Raasi and Wolf, 2007).
Many  of  the  ERAD  components  mentioned  were  first 
identified in yeast. Interestingly, mammals contain additional 
ERAD components for which no counterparts exist in yeast, 
which suggests that mammals use a more elaborate repertoire of 
proteins in ERAD (Carvalho et al., 2006; Jentsch and Rumpf, 
2007; Kanehara et al., 2007).
In this paper, we demonstrate that human ubiquilin proteins 
(Wu et al., 1999; Mah et al., 2000; Kleijnen et al., 2000) that are 
found in the cytoplasm and nucleoplasm (Mah et al., 2000), and 
which are believed to function as ubiquitin–proteasome shuttle 
factors, interact with erasin, an ER localized protein (Liang et al., 
2006), in a novel complex that functions in ERAD. Using a vari-
ety of techniques, including in vitro binding assays, coimmuno-
precipitation and biochemical fractionation of proteins from cells, 
and silencing of the proteins in cells and worms, we obtained evi-
dence in support of this novel complex in ERAD.
Results
In vitro interaction between  
erasin and ubiquilin
A yeast two-hybrid (Y2H) screen using the central domain of human   
ubiquilin-1 (UBQLN1UBLUBA; Fig. 1 A) netted four clones 
containing different portions of the N-terminal end of erasin, an 
ER-localized protein that promotes ERAD (Liang et al., 2006). The 
longest clone interacted 100-fold stronger with the same ubiquilin 
bait than with the UBA domain of ubiquilin or with unrelated baits, 
which indicates strong and specific interaction between erasin and 
the central domain of ubiquilin (Fig. 1 B).
To confirm binding, and to map the erasin-binding site in 
ubiquilin-1, we conducted GST pull-down experiments exam-
ining whether GST fusions of different regions of ubiquilin-1 203 INTERACTION OF ERASIN WITH UBIQUILIN AND P97/VCP • Lim et al.
Indeed, more ubiquilin was coimmunoprecipitated with erasin or 
p97/VCP proteins, or vice versa, in cells cultured in the presence 
of MG132 than in the absence of the inhibitor (Fig. 2, A and B). 
Furthermore, more 6 subunit components of the proteasome and 
ubiquitinated proteins were coimmunoprecipitated with ubiquilin, 
erasin, and p97/VCP proteins after proteasome inhibition (Fig. 2, 
A and B). Interestingly, the amount of p97/VCP or erasin proteins 
that coimmunoprecipitated with each other was not altered after 
proteasome inhibition (Fig. 2, A and B), which indicates that asso-
ciation of ubiquilin, but not p97/VCP, with erasin is regulated by 
proteasome activity.
To explore the interaction between ubiquilin and erasin 
further, we examined whether overexpression of either pro-
tein affects assembly of the complex. Overexpression of era-
sin predominantly increased the amount of p97/VCP, but not 
immunoprecipitations conducted with two different control anti-
bodies (Fig. 2 A, lane 1; and Fig. 2 B, lane 1).
Because erasin promotes ERAD (Liang et al., 2006), we 
considered  that  the  erasin–ubiquilin–p97/VCP  complex  might 
function for this purpose. We reasoned that erasin might recruit 
p97/VCP and ubiquilin to the ER during ERAD for separate pur-
poses: p97/VCP to aid in the retrotranslocation of ERAD substrates 
from the ER, whereas ubiquilin might function to bridge binding 
of the extracted ubiquitinated substrate and the proteasome through 
interaction with its UBA and UBL domains, respectively. To test 
this idea, we made a comparison to see if assembly of the complex 
was altered in cells treated with or without the proteasome inhibitor 
MG132. We predicted that proteasome inhibition would lead to a 
buildup of the complex in cells because of the inability of ubiquilin 
to deliver the ERAD substrate to the proteasome for degradation. 
Figure 1.  Erasin interaction with ubiquilin-1, p97/VCP, and hHR23A. (A) Schematic drawing of ubiquilin-1. Ubiquilin-1UBLUBA (178–428 aa) was 
used as the bait in a Y2H screen. (B) Yeast interaction assay of an erasin prey clone with different baits measured in five independent colonies showing 
the mean and SD (error bars). (C) GST pull-down assays of ubiquilin-1 (UBQ) fusion proteins with 
35S-radiolabeled erasin. (C, right) Schematic drawings 
of the GST constructs and a summary of their binding (+, binding; , no binding). (C, left) Autoradiogram (top panel) and Coomassie-stained gel (bottom 
panel) of the pull-down experiment. (D) Coomassie-stained gel of purified proteins used for pull-down assays. The black line indicates that intervening lanes 
have been spliced out. (E) GST pull-down assays showing that erasin-His binds to GST-ubiquilin but not to GST or GST-hHR23A proteins. The input erasin, 
the recovered erasin, and GST proteins are shown. (F) GST pull-down assays showing that erasin, p97/VCP, and ubiquilin bind together in a trimeric 
complex. The input p97/VCP and erasin proteins and the recovered GST complexes (ponceau) are also shown. Arrowheads indicate the position of full-
length GST-fusion proteins.JCB • VOLUME 187 • NUMBER 2 • 2009   204
untransfected HEK293 cells and found that the two endogenous 
proteins colocalize to some extent (Fig. 2 C, a–c). However, this 
colocalization increased upon treatment of cells with MG132, 
which  is  consistent  with  our  coimmunoprecipitation  results 
(Fig. 2 C, d–f; and Fig. S2). The specificity of the staining is   
illustrated by loss of colocalization of the proteins after siRNA 
knockdown of either protein (Fig. 2 C, g–l).
Ubiquilin is recruited to the ER  
during ERAD
We hypothesized that if ubiquilin interacts with erasin during 
ERAD, then overexpression of an ERAD substrate should in-
crease the likelihood of observing interaction of the proteins. 
We  monitored  ubiquilin  binding  at  the  ER  by  fractionating   
homogenates of cells in which we either artificially induced, or 
did not induce, ERAD on density gradients (Fig. 3 A). The ER 
ubiquilin, that coimmunoprecipitated with erasin (Fig. 2 A). How-
ever, overexpression of ubiquilin-1 increased the amount of 
ubiquilin-1, but not p97/VCP, that coimmunoprecipitated with 
erasin (Fig. 2 A). Similar results were found upon repetition of 
the experiments with cells treated with MG132: binding of ubiq-
uilin to erasin was sensitive to both proteasome inhibition and 
ubiquilin expression (Fig. 2 A, last four lanes). Interestingly, 
overexpression of ubiquilin resulted in increased amounts of 
polyubiquitinated proteins that coimmunoprecipitated with era-
sin, which was especially evident after proteasome inhibition 
(Fig. 2 A).
Proteasome inhibition leads to increased 
colocalization of ubiquilin with erasin
To obtain additional evidence that ubiquilin and erasin interact 
in cells, we performed double immunofluorescence staining of 
Figure 2.  Erasin, ubiquilin, and p97/VCP coimmunoprecipitate with each other in cells. (A) HEK293 cells were either left untransfected (lanes 1, 2, and 6), 
transfected with either erasin (lanes 3 and 7) or ubiquilin-1 cDNA (lane 4 and 8), or cotransfected with both cDNAs (lane 5 and 9). After 20 h, MG132 was 
added for 4 h to one set of the cultures (lanes 6–9), whereas the other set was left untreated (lanes 1–5). Equivalent amounts of protein lysates were used for 
immunoprecipitation using either an erasin antibody (lanes 2–9) or control IgG antibody (lane 1). The immunoprecipitates as well as 1/10 the amount of 
each protein lysate were probed by immunoblotting for the indicated proteins. (B) Similar to A except that cells were not transfected and the antibodies used 
for immunoprecipitation were a different control antibody (lanes 1 and 2), a ubiquilin antibody (lanes 3 and 4), and a p97/VCP antibody (lanes 5 and 6). 
(lanes 7 and 8) Blots for proteins in equal amounts of the lysates used in the experiments. (C) Double immunofluorescence localization of ubiquilin and erasin 
proteins in HEK293 cells that were either not treated () or treated (+) with MG132, or transfected with siRNAs designed to knock down ubiquilin-1 and 
ubiquilin-2 proteins together, or erasin protein alone. Quantification of the colocalization of the proteins is provided in Fig. S3. Bar, 5 µm.205 INTERACTION OF ERASIN WITH UBIQUILIN AND P97/VCP • Lim et al.
misfolding and increased ERAD, also promoted ubiquilin migra-
tion to the ER (Fig. 3, E and F). These results collectively suggest 
that ubiquilin may be recruited to the ER for ERAD.
Ubiquilin promotes degradation  
of membrane-bound and luminal  
ERAD substrates
We next investigated whether reduction of ubiquilin in HEK293 
cells  affects  the  turnover  of  the  two  classical  ERAD  sub-
strates: CD3 and 1ATNHK. siRNA-induced knockdown of 
ubiquilin-1 and -2 proteins in HEK293-CD3 cells, a HEK293 
cell line stably expressing orphan CD3 protein (Ballar et al., 
2007), slowed degradation of CD3, whereas overexpression 
of  ubiquilin-1  slightly  enhanced  CD3  turnover  (Fig.  4 A). 
Similarly, knockdown of the ubiquilin proteins stalled turnover 
of 1ATNHK (Fig. 4, B and D). Because of their association 
with each other, we also examined if loss of erasin expression   
fractionated mainly across the middle-to-heavy-density portions 
of the gradients, as revealed by the distribution of calnexin, a 
classical ER marker (Fig. 3 A). Erasin cofractionated with cal-
nexin, as expected. In untreated HEK293 cells, only a faint 
amount of ubiquilin cofractionated with erasin, with the vast ma-
jority of the protein located in lower density end of the gradient   
(Fig. 3, A and F). In contrast, MG132 treatment increased mi-
gration of ubiquilin toward the ER-containing fractions, which 
were also enriched for ubiquitinated proteins (Fig. 3, B and F).   
Similarly,  overexpression  of  the  ERAD  substrates  CD3,  a 
membrane-bound protein, or 1-anti-trypsin null Hong Kong 
mutant  (1ATNHK),  a  misfolded  luminal  protein,  also  pro-
moted migration of ubiquilin to the ER fractions (Fig. 3, C, D, 
and F). In contrast, overexpression of wild-type 1AT, which 
is not misfolded and should not be a target for ERAD, did not 
promote migration of ubiquilin to the ER (Fig. 3, D and F). 
Treatment of cells with tunicamycin, which causes protein   
Figure  3.  Proteasome  inhibition  or  expres-
sion of ERAD substrates leads to a redistribu-
tion of ubiquilin to the ER. Immunoblot analysis 
of  HEK293  cell  homogenates  separated  on 
0–25% iodixanol gradients. (A–E) The panels 
show the distribution of erasin, calnexin, and 
ubiquilin in fractions of the gradient (heavy, 
bottom; light, top) of cells that were either left 
untreated; treated with MG132 for 4 h; trans-
fected with either CD3, 1ATNHK, or wild-
type 1AT cDNAs; or treated with tunicamycin 
for 4 h (+Tun). Ubiquitin immunoreactivity is 
shown for the MG132 and +MG132 and 
treatments. Because its profile did not change 
significantly, p97/VCP is only shown for the 
control. (F) The amount of ubiquilin in the ER 
fractions was estimated by dividing the inten-
sity of the anti-ubiquilin–immunoreactive bands 
in nine fractions surrounding the calnexin peak 
(boxed with broken lines in A–E) by the sum of 
the bands in the whole gradient.JCB • VOLUME 187 • NUMBER 2 • 2009   206
affects the turnover of the substrates. Like ubiquilin, knockdown 
of  erasin  expression  reduced  degradation  of  both  substrates   
(Fig. 4, C and D; Liang et al., 2006). These results strongly 
suggest that both ubiquilin and erasin promote degradation of 
membrane and luminal ERAD substrates.
Expression of dominant-negative erasin 
mutants inhibits ERAD
To confirm that the function of erasin interaction with ubiq-
uilin  is  connected  with  ERAD,  we  overexpressed  erasin   
cDNAs encoding different portions of the protein, expecting 
that  mutants  containing  the  ubiquilin-binding  site  would 
compete for ubiquilin binding but would not create a func-
tional  ERAD  complex.  The  erasin  mutants  selected  were 
chosen based on their in vitro ubiquilin-binding properties 
(Fig. S1). We selected erasin fragments 1–310 aa and 1–168 
aa  as  putative  dominant-negative  candidates  because  they 
both bound ubiquilin-1 but are not targeted to the ER (Liang 
et al., 2006), and erasin fragment 414–508 aa as an ineffec-
tive mutant because it was devoid of ubiquilin-1 binding.   
We compared the rate of turnover of CD3, stably expressed in 
HEK293 cells, after overexpression of the mutant constructs. 
As shown in Fig. 5 (A and B), erasin fragments 1–310 and 
1–168 both slowed the turnover of CD3, but the 414–508 
fragment had little effect. Furthermore, consistent with our 
idea  of  how  the  dominant-negative  erasin  mutants  might 
function, expression of the 1–310-aa erasin mutant displaced 
ubiquilin  binding  from  the  ER  (Fig.  5  C).  These  studies 
strongly suggest that proper binding of ubiquilin with erasin 
at the ER is required for promoting ERAD.
Abrogation of MG132-induced 
accumulation of ubiquilin, p97/VCP,  
and proteasomes in microsomes after 
erasin knockdown
The preceding results were in accord with the notion that erasin 
functions to recruit p97/VCP and ubiquilin to the ER during 
ERAD. To obtain additional evidence in support of this idea and 
to examine if ubiquilin, in turn, functions to recruit proteasomes 
to the ER during ERAD, we compared the protein composition 
Figure 4.  Knockdown of ubiquilin or erasin proteins impedes ERAD. (A) HEK293-CD3 cells were transfected with either a ubiquilin-1 expression plasmid, 
the empty vector, or with UBQLN1 and UBQLN2 siRNAs. 48 h after transfection, cycloheximide was added to the cultures, and protein lysates were col-
lected at intervals as indicated. Equal amounts of protein lysates were immunoblotted for CD3 (HA-tag), ubiquilin, and actin. The graph shows the profile 
of CD3 turnover determined from three independent experiments showing the mean and the SD (error bars). (B–D) Similar to A, except that turnover of 
1ATNHK was analyzed after knockdown of either ubiquilin (B) or erasin (C). In these experiments, HEK293 cells were transfected with an 1ATNHK-HA 
expression construct 40 h after transfection of the siRNAs, with the turnover studies conducted 20 h later. Equal amounts of protein were immunoblotted 
for 1ATNHK (HA-tag), tubulin, and erasin or ubiquilin, depending on which of them was knocked down. (D) Quantification of 1ATNHK turnover after 
knockdown of either ubiquilin or erasin proteins, determined from three separate experiments showing the mean and SD (error bars).207 INTERACTION OF ERASIN WITH UBIQUILIN AND P97/VCP • Lim et al.
erasin knockdown in both MG132-treated and untreated cultures 
(Fig. 6 A), which suggests that p97/VCP binding to microsomes 
is  somewhat  dependent  on  erasin  expression.  Similarly,  the 
amounts of ubiquilin, Rpt1, and 6 subunit in microsomes of 
cells depleted of erasin were all reduced compared with cells in 
which erasin levels were not altered, but only in cells that were 
treated with MG132 (Fig. 6 A).
The preceding results were in accord with the idea that 
erasin located in the ER binds ubiquilin, which, in turn, binds 
the proteasome. However, because reduction of erasin expres-
sion by RNAi resulted in a concomitant reduction in ubiquilin 
protein in microsomes, we next asked if reduction of ubiquilin 
protein alone was sufficient to reduce proteasome recruitment 
to the ER during ERAD. As shown in Fig. 6 B, microsomes of 
cells transfected with siRNA against ubiquilin-1 and -2, or a 
combination  of  siRNAs  against  both  ubiquilins  and  erasin, 
failed to manifest the MG132-dependent increase in protea-
some binding, as measured using three different proteasome 
components, that occurred in cells in which erasin or ubiquilin 
expression was not silenced. Furthermore, consistent with the 
idea that knockdown of erasin or ubiquilin proteins reduces 
of microsomes isolated from HEK293 cells expressing endoge-
nous levels of erasin and ubiquilin proteins with those from 
cells silenced for expression of erasin and/or ubiquilin-1 and -2. 
Microsomes contain an enriched source of ER fragments, which 
we used to monitor changes in protein composition of the ER.
As shown in Fig. 6 A, four ER proteins—erasin, cal-
nexin, derlin-1, and derlin-2—were detected in the microsome 
fraction but not the cytosolic fraction, which confirms that   
our microsome preparations were indeed enriched for ER 
components. Microsomes that were isolated from cells trans-
fected with erasin siRNAs contained 80% less erasin than 
those isolated from mock-transfected cells, which indicates 
successful depletion of erasin protein content of microsomes 
by RNAi (Fig. 6 A).
We next examined whether microsomes of cells depleted 
of erasin contained less ubiquilin, p97/VCP, and proteasomes 
than those of cells not depleted of erasin. We used antibodies 
against the 6 subunit and Rpt1, which are contained in the 20S 
catalytic core and 19S complex of the proteasome (Pickart and 
Cohen 2004), respectively, as markers for proteasomes. The 
amount of p97/VCP in microsomes was reduced by 50% after 
Figure 5.  Dominant-negative erasin fragments interfere with CD3 degradation. (A) HEK293-CD3 cells were either mock transfected (control) or trans-
fected with erasin deletion constructs encoding portions of the erasin polypeptide from amino acids 1–310, 414–508, or 1–168. Protein turnover was 
analyzed similar to Fig 4. Both a long and short exposure of the CD3 signal is shown. Please note that the erasin 414–508 runs aberrantly on SDS-PAGE. 
(B) Graphs of CD3 turnover determined from three separate experiments showing the mean and SD (error bars). (C) Immunoblots showing ubiquilin and 
erasin distribution in fractions of HEK293-CD3 cell homogenates separated on 0–25% iodixanol gradients.JCB • VOLUME 187 • NUMBER 2 • 2009   208
Figure 6.  Microsomes of cells depleted of erasin contain less ubiquilin, p97/VCP, and proteasomes. HEK293 cells were either mock transfected or trans-
fected with siRNAs against erasin. 72 h after transfection, the cells were incubated with MG132 for an additional 4 h, whereas a duplicate set was left 
untreated. (A) Equal amounts of protein in microsome and supernatant fractions of the cells were separated by SDS-PAGE and probed for the proteins 
shown. Blots of equal amounts of proteins in total lysates of the cultures are also shown. (B) Similar to A, except that this time erasin or ubiquilin-1 and -2 209 INTERACTION OF ERASIN WITH UBIQUILIN AND P97/VCP • Lim et al.
Ubiquilin and erasin expression is induced 
by ER stress in Caenorhabditis elegans
Because chronic disruption of ERAD causes ER stress, we pre-
dicted that loss of ubiquilin or erasin expression would lead to 
ER stress. We tested this hypothesis in C. elegans. Worms were 
used for several reasons. First, they are an ideal model organism 
to study ER stress, with several mutant and reporter lines avail-
able for such purposes (Shen et al., 2001, 2005). Second, unlike 
mammals, worms contain single ubiquilin and erasin genes, 
making it easier to inactivate the genes without the complica-
tion of compensation by redundant family members. And third, 
because of the efficacy of RNAi in worms.
We first determined whether ubiquilin and erasin are part 
of the compendium of genes that are induced during the UPR. 
Accordingly, worms containing an integrated hsp4::gfp tran-
scriptional reporter, widely used to monitor ER stress (Shen 
et al., 2001; Calfon et al., 2002), were treated with tunicamycin 
to induce ER stress for different periods of time. As expected, 
transcripts of the classical ER stress-regulated gene, hsp-4 (the 
worm homologue of human BiP), were induced by the drug 
treatment, with peak expression occurring 4 h after drug treat-
ment, but then its expression was attenuated (Fig. 7, A and B). 
Interestingly,  both  ubiquilin  and  erasin  transcripts  increased 
with somewhat similar profiles to that of hsp-4, which suggests 
that they are part of the UPR response (Fig. 7, A–D). Expres-
sion of ama-1, which is not part of the UPR, did not change over 
this period, as expected (Fig. 7 A).
An examination of the changes in proteins in the tunicamycin-
treated worms revealed that the GFP protein expression, under 
the control of the hsp-4 promoter (Fig. 7 E), increased tempo-
rally, with high accumulation observed 16 h after drug treat-
ment (Fig. 7 F). This was accompanied by a parallel increase in 
ubiquitinated proteins, which is consistent with the idea that 
tunicamycin treatment causes accumulation of misfolded pro-
teins in the worms. Ubiquilin and erasin protein levels increased 
fivefold and threefold, respectively, 4 h after tunicamycin treat-
ment, but thereafter their levels remained constant. The differ-
ence between the levels of ubiquilin and erasin transcripts and 
their respective proteins suggests possible posttranscriptional 
and/or posttranslational regulation of the genes.
To determine if ubiquilin and erasin promoters are di-
rect targets of the UPR, we cloned the GFP open reading 
frame downstream of a 2-kb fragment containing the putative   
C. elegans ubiquilin promoter and isolated transgenic worms 
containing the integrated ubiquilin::gfp promoter fusion plasmid   
(Fig. 7 G). As shown in Fig. 7 (H–J), ubiquilin::gfp transgenic 
worms manifested a tunicamycin dose-dependent increase in 
GFP expression by both immunoblotting and immunofluores-
cence microscopy. Interestingly, GFP expression was particularly 
proteasome recruitment to the ER, we found that proteasome 
activity in microsomes isolated cells stably expressing CD3 in 
which ubiquilin or erasin proteins were knocked down was re-
duced 20% compared with cells in which the proteins were 
not targeted for RNAi (Fig. 6 C).
Effect of erasin knockdown on 
coimmunoprecipitation of p97/VCP, 
ubiquilin, and the proteasome
We next examined whether reduction of erasin in cells affects 
assembly of the ERAD complex. HEK293 cells transfected 
with erasin siRNAs, or cells that were mock transfected, were 
cultured  with  or  without  MG132,  and  ubiquilin  proteins 
were immunoprecipitated from the cells. The precipitates were   
examined for erasin, p97/VCP, and the proteasome by immuno-
blotting. As shown in Fig. 6 D, more erasin, p97/VCP, and 
the 6 subunit of the proteasome coimmunoprecipitated with 
ubiquilin from cells treated with MG132 than from those not 
treated with MG132. Cells that were transfected with siRNAs 
against erasin and treated with MG132 contained lower lev-
els of erasin, p97/VCP, and the 6 subunit than untransfected 
cells treated with MG132, which suggests that knockdown of 
erasin expression interferes with formation or stability of the 
ERAD complex. Immunoblot analysis of total protein lysates 
confirmed that erasin levels were reduced by 80% after the 
knockdown. Ubiquilin levels were slightly elevated in the 
erasin knockdown cells compared with the mock-transfected 
cells, but the levels of p97/VCP and the 6 subunit remained 
relatively constant. Thus, the decreased coimmunoprecipi-
tation of p97/VCP and the 6 subunit with ubiquilin after 
erasin knockdown was not caused by a global change in the 
expression of the proteins. We should point out that the cells 
depleted of erasin still displayed a slight MG132-dependent 
increase in the coimmunoprecipitation of p97/VCP and the 
6 subunit with ubiquilin. At present, we cannot distinguish 
whether this is from incomplete silencing of erasin expres-
sion or interactions mediated by proteins other than erasin. 
Nevertheless, these data suggest that erasin may be required 
for the assembly of ubiquilin, p97/VCP, and the proteasome 
in a complex.
To demonstrate that ubiquilin functions as a shuttle fac-
tor in delivery of ERAD substrates to the proteasome for 
degradation, we immunoprecipitated ubiquilin from HEK293 
cells stably expressing CD3 and probed them for the pres-
ence of CD3 and the proteasome. As shown in Fig. 6 E, 
CD3 as well as 19 and 20S components of the proteasome 
were found in the ubiquilin immunoprecipitates, and, as ex-
pected, more of them were present after MG132 treatment of 
the cells.
were knocked down separately, or simultaneously. Additionally, only the microsome fractions were probed for proteasome subunits (6, 7, and Rpn10), 
ubiquilin, and calnexin (to ensure equal protein loading). Also shown are the blots of the total lysates of the cultures. (C) Assays of proteasome activity in 
microsomes and total lysates of HEK293-CD3 cells that were either mock transfected or transfected with siRNAs against erasin or ubiquilin-1 and -2 of 
three separate cultures showing the mean and SD (error bars). (D) A repeat of the experiment shown in A, but this time we immunoprecipitated ubiquilin 
from the cells and examined equal fractions of the precipitates by immunoblotting for the indicated proteins. Blots of the total lysates are also shown.   
(E) Ubiquilin was immunoprecipitated from HEK293-CD3 cells that were either left untreated or treated with MG132 for 4 h. Equal portions of the   
immunoprecipitates were probed for the proteins shown.
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Figure 7.  Ubiquilin and erasin expression are induced by ER stress in C. elegans. (A) Mixed-stage zcls4 [hsp-4::GFP] worms were grown on plates with 
28 µg/ml tunicamycin for 0, 4, 8, 16, and 48 h, and transcript levels of hsp-4, ubiquilin, erasin, and ama-I were measured by semiquantitative PCR and 
gel electrophoresis. Quantification of Hsp-4 (B), ubiquilin (C), and erasin (D) expression relative to the 0 time point. Similar trends were observed in two 
other experiments. (E) Schematic diagram of the hsp-4::GFP reporter construct. (F) Immunoblot analysis of equal amounts of protein lysate (two independent 
samples for each time point) prepared from worms treated with 28 µg/ml of tunicamycin for the periods indicated. An unknown protein whose expression 
was insensitive to ER stress was used as a loading control. (G) Schematic diagram of the C. elegans ubiquilin promoter fragment fused to GFP. (H) Immuno-
blot analysis of equal amounts of protein lysate of worms treated with 0, 2.5, or 28 µg/ml tunicamycin for 24 h. (I) Quantification of GFP expression 
determined by scanning of immunoblots as described in H showing the mean and SD (error bars) seen in three different experiments. (J) GFP fluorescence 
of worms containing the integrated ubiquilin::GFP fusion construct treated for 24 h with 0, 2.5, or 28 µg/ml tunicamycin. Bar, 0.2 mm.211 INTERACTION OF ERASIN WITH UBIQUILIN AND P97/VCP • Lim et al.
to the complex, and that ubiquilin, in turn, recruits protea-
somes. These findings, together with the known functions of 
the proteins with which erasin coimmunoprecipitates, have   
prominent in the pharyngeal muscle, hypodermis, and intestine 
of the worms, which suggests that the reporter might be un-
evenly expressed across the worm. Similarly, worms carrying 
an erasin::GFP reporter were also reported to display a similar   
tunicamycin  dose-dependent  increase  in  GFP  expression   
(Yamauchi et al., 2007). Together, these results suggest that   
ubiquilin and erasin promoters contain UPR-response elements.
Expression of ubiquilin and erasin during 
ER stress is regulated by ire-1
We next investigated which arm of the UPR regulates ubiquilin 
and erasin expression. Like in mammals, the UPR in C. elegans 
is induced through the action of three main sensors: ire-1, pek-1 
(called protein kinase-like ER kinase [PERK] in mammals), 
and atf-6. We used worms containing inactive versions of the 
sensors to determine which pathway regulates tunicamycin   
induction of ubiquilin and erasin expression. In the control wild-
type N2 worms, expression of ubiquilin and erasin transcripts 
increased after 6 h of tunicamycin treatment (Fig. 8). However, 
the induction of both genes was almost completely attenuated in 
ire-1 (v33) mutant worms, and partially attenuated in the atf-6 
(ok551) and pek-1 (ok275) mutants (Fig. 8). Together, these re-
sults indicate that in C. elegans, both ubiquilin and erasin genes 
are chiefly regulated by ire-1.
RNAi of ubiquilin or erasin results in 
accumulation of misfolded proteins and 
induction of ER stress
We next examined whether reduction of ubiquilin or erasin 
expression in worms causes ER stress. Reduction of either ubiqui-
lin or erasin expression in hsp-4::gfp worms by bacteria-mediated 
RNAi resulted in a threefold and fivefold increase in GFP ex-
pression, respectively (Fig. 9 A). In both cases, GFP expression 
was lower than that produced by treatment of the worms with 
tunicamycin, which suggests that loss of ubiquilin or erasin ex-
pression induces more subtle ER stress than that produced by 
tunicamycin treatment. Interestingly, knockdown of ubiquilin 
expression led to an induction of erasin expression, and vice 
versa (Fig. 9, A and B). Moreover, RNAi of either ubiquilin or 
erasin led to an accumulation of ubiquitinated proteins in the 
worms, which is consistent with the idea that the proteins func-
tion in the disposal of misfolded proteins from cells.
Reduction of worm lifespan by RNAi  
of ubiquilin or erasin
Finally, we investigated whether RNAi of ubiquilin or erasin   
alters lifespan in the worm. As shown in Fig. 9 C, RNAi of erasin 
shortened lifespan in worms from a mean survival time of 21 d 
to 12 d, whereas RNAi of ubiquilin reduced it to 17 d. Together, 
these data suggest that loss of either ubiquilin or erasin expres-
sion shortens the worm lifespan.
Discussion
Here, we describe a novel erasin-containing protein complex 
involved in ERAD in human cells. Our results suggest that 
erasin acts as a platform to recruit both p97/VCP and ubiquilin   
Figure 8.  The ire-1 branch of the UPR regulates induction of ubiquilin and 
erasin expression during ER stress. (A) Mixed-stage worms of the indicated 
mutant strains were grown on plates with 28 µg/ml tunicamycin for 0 
or 6 h. Transcript levels of hsp-4 (regulated by ire-1; Shen et al., 2001), 
ubiquilin, erasin, and CBP were analyzed by PCR and agarose gel elec-
trophoresis. (B–E) Quantification of the relative change in transcript expres-
sion determined from the experiment shown in A. Levels were normalized 
to the 0 h time point in each mutant. Similar results were observed in two 
other experiments.JCB • VOLUME 187 • NUMBER 2 • 2009   212
enabled us to construct a model of how the complex might 
function in ERAD. Specifically, we propose that misfolded 
protein substrates that are extracted from the ER interact se-
quentially with a series of proteins and are eventually delivered 
to the terminal degradation apparatus of the cell, the protea-
some (Fig. 10). The model we propose predicts that delivery 
of ER-derived substrates to the proteasome is highly coupled 
in a manner that prevents premature release of the substrate 
into the cytosol, where it might accumulate or aggregate into a 
potentially toxic species.
Our model focuses on erasin, an ER resident protein that 
is thought to embed into the membrane via a short hydrophobic 
sequence close to its C terminus, with the remainder of the pro-
tein facing the cytoplasm (Fig. 10 A; Liang et al., 2006). We 
propose that erasin forms a complex with derlin and gp78/Hrd1 
ligases either through direct or indirect interaction of the pro-
teins, which is supported by coprecipitation of the proteins   
(Liang et al., 2006; Mueller et al., 2008). Erasin recruits p97/VCP 
to the complex via direct interaction with its UBX domain 
(Fig. 10 B; Liang et al., 2006). On the basis of previous studies of 
the mechanism by which ERAD is thought to occur (Ye et al., 
2001; Jarosch et al., 2002; Vembar and Brodsky, 2008), we 
propose that the misfolded substrate in the ER is polyubiqui-
tinated by gp78/Hrd1 and/or related ubiquitin ligases and ex-
tracted through the derlin channel by p97/VCP (Fig. 10 B). We 
speculate that the polyubiquitin chain that is conjugated onto 
the substrate is then recognized by the UBA domain of ubiqui-
lin, which promotes ubiquilin binding to erasin, or vice versa 
(Fig. 10 B). Ubiquilin in turn recruits the proteasome to the 
ERAD complex, probably via interactions with its UBL do-
main, bringing it in close proximity for the delivery and degra-
dation of the ERAD substrate that is anchored to the UBA 
domain of ubiquilin (Fig. 10, C and D). After degradation of 
the substrate, we speculate that the complex most likely dis-
assembles. The model incorporates many of our results with the 
well-established functions of the proteins mentioned. However, 
gaps remain, as discussed below.
A key aspect of our model emphasizes the apparent dif-
ference in the binding of p97/VCP and ubiquilin proteins with 
erasin that we found occurs during ERAD. According to our in 
Figure 9.  Knockdown of ubiquilin or erasin proteins in worms results in the induction of the ER stress reporter hsp-4::GFP, accumulation of misfolded 
proteins, and a shorter lifespan. (A) Mixed-stage zcls4 [hsp-4::GFP] worms were either fed standard bacteria in the presence or absence of 28 µg/ml 
tunicamycin or bacteria to induce RNAi of the ubiquilin gene. Immunoblot analysis of equal amounts of protein lysate prepared after 48 h of treatment for 
GFP, ubiquilin, erasin, ubiquitin, and an unknown protein used as a loading control. (B) Identical to A, except that worms were fed bacteria to specifically 
knock down erasin. (C) Lifespan curves comparing N2 (wild-type) worms fed bacteria transformed with the empty RNAi vector or the vector containing 
cDNAs to induce RNAi of either ubiquilin or erasin genes. Results are cumulative from three independent experiments, with ≥60 animals per trial. Log-rank 
(Mantel-Cox) and Gehan-Breslow-Wilcoxon tests, P < 0.0001 versus control.213 INTERACTION OF ERASIN WITH UBIQUILIN AND P97/VCP • Lim et al.
because of the inability of ubiquilin to deliver its bound sub-
strate to the proteasome for degradation.
The ERAD-enhanced and proteasome inhibition–dependent 
increase in ubiquilin interaction with erasin provides important 
clues as to the possible mechanisms by which the complex 
is assembled. We speculate that during ERAD, the polyubiq-
uitinated chain that is conjugated onto the substrate might first 
be recognized by the UBA domain of ubiquilin, bringing it in 
closer proximity to erasin, thereby enhancing their probability 
of interaction. However, we cannot rule out the possibility that 
ubiquilin first interacts with erasin, and then with the polyubiq-
uitinated substrate. Both mechanisms are supported by in vitro 
binding studies. For example, we found that ubiquilin binds era-
sin with very high affinity (with a KD of 30 nm; Fig. S4). Also, 
the UBA domain of ubiquilin binds a wide variety of ubiquitin 
vitro  binding  results,  recombinant  ubiquilin,  p97/VCP,  and 
erasin proteins can all bind together in one complex. Yet ac-
cording  to  immunoprecipitation  studies,  we  noticed  differ-
ences in the amount of the proteins that were bound to erasin 
under different conditions: the amount of p97/VCP that was 
bound to erasin was dependent on the amount of erasin protein 
expressed, whereas ubiquilin binding to erasin was stimulated 
by either overexpression of ubiquilin itself, by proteasome in-
hibition, or by enhancing ERAD. On the basis of these results, 
we suggest that binding of p97/VCP to erasin is governed 
principally by the amount of erasin in cells, whereas binding 
of ubiquilin to erasin is transitory, and might only occur dur-
ing delivery of the polyubiquitinated substrate to the protea-
some for degradation. According to this model, inhibition of 
the proteasome would arrest binding of ubiquilin with erasin 
Figure 10.  Model of the mammalian erasin-assembled ERAD complex. A schematic diagram of the putative erasin-containing ERAD complex (see Discussion).JCB • VOLUME 187 • NUMBER 2 • 2009   214
Our finding, that erasin and ubiquilin are induced by ER 
stress, might help explain the increased staining of the proteins 
found in brains of individuals afflicted with Alzheimer’s disease 
(AD; Mah et al., 2000; Liang et al., 2006). The simplest expla-
nation is that ER stress is involved in AD pathogenesis. Obvi-
ously,  this  remains  speculative,  but  it  is  consistent  with  the 
observation that UPR markers are activated AD (Hamos et al., 
1991; Hoozemans et al., 2005). In fact, ER stress has now been 
linked to other neurodegenerative diseases, such as amyotrophic 
lateral sclerosis and Huntington’s disease (Nishitoh et al., 2008; 
Duennwald and Lindquist, 2008). It is worth noting that in the 
case  of  Huntington’s  disease,  overexpression  of  ubiquilin, 
which we now show here promotes ERAD, suppresses the tox-
icity of expanded polyglutamine proteins in cell and animal 
models of the disease (Wang et al., 2006).
We found that reduction of ubiquilin or erasin expression 
shortened the life span of worms, which suggests that they are 
important for normal survival. Similar to worms, loss of ubiquilin 
in Drosophila shortens life span (Li et al., 2007). To our knowl-
edge, there is only one other report of the consequences of loss of 
erasin in animals: knockdown by morpholino in zebrafish, which 
produced highly abnormal embryos (Pickart et al., 2006).
In summary, our results provide strong evidence that ubiq-
uilin and erasin proteins bind together in a novel ERAD com-
plex and that they play important roles in regulating protein 
degradation and ER stress.
Materials and methods
Y2H experiments
A cDNA fragment encoding the central domain of ubiquilin-1 was cloned 
in-frame with the LexA coding sequence in the yeast Y2H bait vector, 
pEG202 (Golemis et al., 2008). The resulting bait was transformed into 
yeast strain EGY48, which was then used to screen a human fetal brain 
cDNA library for interactors by selection on plates lacking uracil, histi-
dine, tryptophan, and leucine (Mah et al., 2000). Putative interactors 
were further characterized by DNA sequencing and by interaction with 
additional baits as listed in Fig. 1 B. The strength of interaction between 
the different preys and baits was quantified by -galactosidase activity as-
says using the chromogenic substrate o-nitrophenyl--d-galactopyranoside 
(Golemis et al., 2008).
In vitro transcription/translation and GST pull-down assays
[
35S]methionine-radiolabeled  full-length  and  partial-length  erasin  and 
lamin polypeptides were synthesized in rabbit reticulocyte lysates using 
a  coupled  in  vitro  transcription  and  translation  system  (Promega).  The   
35S-labeled proteins were incubated with 3 µg of purified GST-His or differ-
ent GST–ubiquilin-1 fusion proteins for 1 h at 4°C under constant rotation. 
Glutathione-agarose (Sigma-Aldrich) was then added to the mixtures and 
the incubation was continued for another 1 h. The agarose beads were 
recovered by centrifugation and washed in standard PBS containing 0.5% 
NP-40, then equal portions of the samples were separated by SDS-PAGE 
and stained with Coomassie blue, and an autoradiogram was prepared.
Using a similar strategy, we identified the ubiquilin-binding site in 
erasin. The deletion constructs and the results of this mapping study are 
shown in Fig. S1.
In vitro binding of full-length recombinant proteins to one another 
was analyzed by GST pull-down assays. Recombinant full-length mouse 
p97/VCP, human erasin, human hHR23A (the expression construct was 
provided  by  the  late  C.  Pickart,  Johns  Hopkins  University,  Baltimore, 
MD),  and  human  ubiquilin-1  proteins  were  expressed  in  BL21(DE3) 
bacteria as either His- or GST-tagged fusion proteins. The p97/VCP-His 
and  erasin-His  bacterially  expressed  proteins  were  purified  by  nickel– 
nitrilotriacetic acid–agarose (QIAGEN) affinity chromatography and the 
GST–ubiquilin-1 and GST-hHR23A proteins by glutathione-agarose affinity 
chromatography. The purified proteins were dialyzed against 20 mM Tris,   
moieties with similar high affinity, including K48-linked tetra-
ubiquitin that is principally conjugated onto proteins that are 
degraded by proteasomes (Ko et al., 2004; Massey et al., 2004; 
Raasi et al., 2005).
In the next step of our model, we propose that erasin-
bound ubiquilin recruits proteasomes to the complex, probably 
via interaction of its UBL domain with subunits of the protea-
some. This proposal is based on previous demonstration that 
the UBL domain binds the proteasome (Kleijnen et al., 2000; 
Ko et al., 2004). In support of such a mechanism, we found 
that silencing of ubiquilin expression abrogated proteasome 
recruitment to the erasin complex. Furthermore, silencing of 
erasin expression led to a similar outcome, which is expected 
because erasin serves to recruit ubiquilin to the complex.   
Finally,  inhibition  of  the  proteasome  resulted  in  increased 
amounts of CD3 (the ERAD substrate) and more proteasome 
subunits  that  coimmunoprecipitated  with  ubiquilin,  as  pre-
dicted by the model.
The recruitment of proteasomes to the ER by the ERAD 
complex  we  have  described  is  somewhat  similar  to  JNK- 
associated  membrane  protein  (JAMP),  another  protein  in-
volved in ERAD (Tcherpakov et al., 2008, 2009). We there-
fore examined whether erasin and JAMP are part of the same 
complex, but found that JAMP does not coimmunoprecipitate 
with erasin (Fig. S5), which suggests that they form distinct 
complexes.  Additional  coimmunoprecipitation  studies  indi-
cated that Ufd1, a p97/VCP-interacting factor, is not associ-
ated with erasin (Fig. S5), which is similar to a previous report 
showing that Ufd1 and p97/VCP are not always found bound 
together in ERAD (Ballar et al., 2006).
Our in vitro binding results indicated that ubiquilin-1, 
but not hHR23A, binds erasin, which suggests that these two 
human ubiquitin–proteasome shuttle proteins cannot substi-
tute for each other, at least for binding to the erasin-containing 
ERAD complex. In a recent study, ubiquilins were found to   
interact with Herp and regulate degradation of CD3 (Kim   
et al., 2008). Herp is another ER-associated protein that shares 
many properties with erasin. Its topology is similar to that of 
erasin (Kokame et al., 2000), and like erasin, it associates with 
derlin-1, p97/VCP, and Hrd1 (Schulze et al., 2005; Okuda-
Shimizu and Hendershot, 2007). Also, Herp expression is in-
duced by ER stress (Kokame et al., 2000; Ma and Hendershot, 
2004). At present, it is unclear whether ubiquilins discriminate 
between or bind equally well to erasin and Herp. Interestingly, 
Herp  does  not  coimmunoprecipitate  with  erasin  (Fig.  S5), 
which suggests they are in distinct complexes.
In accord with their involvement in ERAD, knockdown of 
either ubiquilin or erasin in C. elegans induced ER stress. The 
results are consistent with the strong coordination that is known 
to exist between ERAD and UPR: interference of ERAD induces 
the UPR, whereas UPR induction increases ERAD capacity 
(Travers et al., 2000). UPR induction of both erasin and ubiqui-
lin genes in C. elegans appeared to be under the control of ire-1. 
The ire-1–dependent regulation of erasin and ubiquilin expres-
sion is in accord with previous studies indicating that this arm 
of the UPR is principally involved in regulating expression of 
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3,000 g for 10 min at 4°C, after which the supernatant was collected and 
layered on top of 10-ml preformed 0–25% iodixanol gradients made with 
buffer B. The layered gradients were then centrifuged at 200,000 g at 4°C 
for 2.5 h in a rotor (SW 41Ti; Beckman Coulter). After centrifugation, 
0.65-ml fractions were collected from the bottom of the tube. An equal vol-
ume of each fraction was immunoblotted for different proteins.
Microsomes  were  prepared  from  HEK293  cells  that  were  either 
mock transfected or transfected with siRNAs (10 nM final concentration) 
against erasin, or ubiquilin-1 and ubiquilin-2 proteins using hypotonic lysis 
and the differential centrifugation procedure (Kokame et al., 2000). In 
brief, after transfection, cells were resuspended in 1 ml of buffer (10 mM 
Hepes-KOH, pH 7.4, 250 mM sucrose, 10 mM KCl, 1.5 mM MgCl2,   
1 mM EDTA, and 1 mM EGTA) and then sheared by passing the suspen-
sion 30 times through a 25-gauge needle. A portion of the sample was 
saved to monitor differences in protein expression between the samples. 
The remainder of the sample was centrifuged at 1,000 g for 5 min at 4°C, 
and the resulting supernatant removed and respun at 100,000 g for 1 h at 
4°C. The resulting pellet and supernatant fractions were either dissolved in 
our standard protein lysis buffer containing protease inhibitors for SDS-
PAGE analysis or used for proteasome activity assays. Equal amounts of 
protein in the supernatant and pellet fractions of microsomes were ana-
lyzed by immunoblotting for the presence of various proteins as shown in 
Fig. 6. Corresponding immunoblots were conducted of the samples that 
were saved before the high-speed centrifugation step.
Proteasome activity was measured using the 20S proteasome ac-
tivity  assay  kit  (Millipore),  which  uses  N-succinyl-Leu-Leu-Val-Try-AMC   
(7-amino-4-methycoumarin)  as  a  fluorogenic  substrate.  In  these  assays, 
equal amounts of protein contained in microsomes prepared from HEK293-
CD3 cells that were either mock transfected or transfected with siRNAs 
against erasin or ubiquilin-1/2 were incubated with the fluorogenic sub-
strate with and without the proteasome inhibitor lactacystin. After 1 h incu-
bation of the reactions at 37°C, the fluorescence (380 nm excitation/460 
nm emission) was measured using a fluorescent plate reader (SpectraMax 
Gemini; MDS Analytical Technologies), and the proteasome activity re-
ported was calculated by subtracting the fluorescence reading of the reac-
tion incubated with lactacystin from that lacking the inhibitor. Proteasome 
activity after erasin and ubiquilin-1/2 knockdown was normalized to that 
in the mock-transfected cells. Proteasome activity was also determined in 
fractions of the total cell lysates that were saved before the microsome 
preparations. The linear responsiveness of the fluorescence reader for the 
activity assays was established using increasing amounts of 7-amino-4-
methycoumarin (Enzo Life Sciences, Inc.).
C. elegans strains and drug treatments
C.  elegans  strains  were  cultivated  under  standard  conditions  (Brenner, 
1974). The strain N2 (Bristol) was used as the wild-type strain. The reporter 
strain zcls4 [hsp-4::GFP] and the mutant strains ire-1 (v33), pek-1 (ok275), 
and atf-6 (ok551) were obtained from the Caenorhabditis Genetics Center, 
University of Minnesota. For the ER stress tests, nematodes were grown on 
plates containing 0, 2.5, or 28 µg/ml of tunicamycin (Sigma-Aldrich) for 
up to 48 h.
PCR analysis of transcripts expressed in worms
Total RNA was isolated from mixed-stage nematodes by using TRIzol re-
agent (Invitrogen). First-strand cDNA was synthesized using oligo-dT primer 
(Invitrogen), and 0.5 µg/µl of the cDNA was amplified using primers for   
ubiquilin (F15C11.2) 5-ATGGCTACAGAGAGTGCACTCATCAAAGTT-3  
and 5-CTATGGAGAGTTGAGAAGACGTTCGACAGC-3; erasin (ZK353.8)   
5-GCTGATCGCGAAGCTGCTCAGAAAAAGTTCGGG-3 and 5-ACGAA-
CTTCCGCACTCCTTGGCATCCCGCG-3; hsp-4 (F43E2.8) 5-CGTGG-
CAAACGCGTACTGTGATGAAGGAGC-3 and 5-CAGTTCATCATGATCC-
TCCGATTGCTCCTC-3; ama-1 (F36A4.7) 5-CAGTGGCTCATGTCGAGTTT-
CCAGA-3 and 5-CGACCTTCTTTCCATCATTCATCGG-3; cAMP response 
element–binding protein (CBP; F40F12.7) 5-ATGCTTGCACTGCATCA-
AGA-3 and 5-TCAATCATGGAACAACTGTG-3; and act-3 (T04C12.4.1)   
5-TTTGTTATTGCCCCAAAAGG-3 and 5-GTCGGTATGGGACAGAA-
GGA-3. The products were separated on a 0.8% agarose gel and visual-
ized by ethidium bromide staining.
RNAi of genes in worms
The entire open reading frame encoding the C. elegans ubiquilin protein 
was cloned between the BglII and KpnI sites of the L4440 vector (provided 
by  B.  Vogel,  University  of  Maryland  Biotechnology  Institute,  Baltimore, 
MD) that is widely used for inducing RNAi in worms using the bacterial 
feeding protocol (Timmons and Fire, 1998; Timmons et al., 2001). An erasin 
pH 8.0, 150 mM NaCl, and 10% glycerol. GST pull-down experiments 
were conducted as follows: the GST proteins were first incubated with   
GS-agarose beads in pull-down buffer (20 mM Tris, pH 8.0, 150 mM 
NaCl, 3 mM MgCl2, 10% glycerol, and 0.1% Triton X-100) for 2 h at 4°C. 
The beads were recovered, washed, and then incubated with various com-
binations of erasin-His, p97/VCP-His, or both erasin-His and p97/VCP-His 
in pull-down buffer for 1.5 h at 4°C. Beads were then washed three 
times with pull-down buffer containing 800 mM NaCl. Proteins that were 
retained on beads were released with SDS sample buffer and analyzed 
by immunoblotting.
Cell culture, DNA and siRNA transfection,  
and immunofluorescence microscopy
HEK293 cells were grown in DME supplemented with 10% FBS. Cells 
were transiently transfected with plasmid DNA using Lipofectamine 2000 
(Invitrogen) or with siRNA SMARTpools (Thermo Fischer Scientific) against 
erasin, ubiquilin-1, or ubiquilin-2 using the DharmaFECT reagent 1 (Thermo 
Fisher Scientific) according to the manufacturer’s instructions. The turnover 
of HA-tagged CD3 and a1ATNHK proteins was measured by immuno-
blotting equal amounts of protein lysate that were collected at various time 
intervals, as indicated in the figures, from cultures to which cycloheximide 
was added to a final concentration 100 µM to block new protein synthesis 
(Liang et al., 2006; Ballar et al., 2007). Association of erasin with JAMP 
was  analyzed  by  coimmunoprecipitation  assays  using  a  FLAG-tagged 
JAMP expression construct (provided by Z. Ronai, Burnham Institute for 
Medical Research, La Jolla, CA). For immunofluorescence microscopy, 
HEK293 cells grown on coverslips were fixed with 4% paraformaldehyde 
and stained with rabbit anti-erasin and mouse anti-ubiquilin primary anti-
bodies followed by fluorescein-conjugated donkey anti–rabbit and rhodamine-
conjugated  donkey  anti–mouse  secondary  antibodies,  after  which  the 
coverslips were mounted onto glass slides using Aqua Polymount (Poly-
sciences, Inc.). Fluorescence images were captured at room temperature 
on an LSM 510 confocal microscope using an Axiovert 100M micro-
scope, a 63× oil-immersion lens (NA 1.4) with Carl Zeiss 4.2 software (all 
from Carl Zeiss, Inc.). Colocalization of the images was performed with 
iVision-Mac software (BioVision Technologies) without any other manipu-
lation of the images. The extent of colocalization of ubiquilin and erasin is 
shown as Fig. S3.
Protein preparation, SDS-PAGE, immunoprecipitation, and 
immunoblotting
For  immunoprecipitation  (IP)  assays,  cells  were  harvested  with  stan-
dard 1× PBS buffer and then collected by centrifugation at 5,000 g for   
5 min. The resulting pellets were resuspended in IP buffer (50 mM Tris-Hcl,   
pH 7.5, 150 mM NaCl, 2 mM EDTA, and 0.1% NP-40), and the cells   
were thoroughly lysed by passage of the mixture 30 times through a   
25-gauge needle. The resulting mixture was centrifuged at 3,000 g for   
10 min, after which the supernatant was used for IP. For these assays,   
5 µl of an appropriate antibody was added together with 100 µl of   
protein A–Sepharose CL-4B beads (GE Healthcare) and the cell supernatant 
containing 500 µg of protein in a 1.5-ml tube. The contents of the tube were 
mixed by rotation for 2 h at 4°C, after which the beads were recovered by 
centrifugation at 5,000 g for 5 min followed by 5 washes with IP buffer. The 
bound proteins were eluted with standard Laemmli gel sample buffer (Laemmli 
1970) and separated by SDS-PAGE. The proteins were then transferred 
onto 0.4-µm-pore-size Immobilon-P membranes (Millipore), according to 
the manufacturer’s instructions, followed by standard immunoblotting of 
proteins using the SuperSignal West Pico detection method (Thermo Fisher 
Scientific). The primary antibodies used in this study were obtained from 
the following sources. Goat polyclonal anti-actin (Santa Cruz Biotechnol-
ogy Inc.); rabbit polyclonal antibodies anti-erasin, anti-ubiquilin, anti-p97/
VCP, anti-GST (generated by our laboratories), anti–derlin-1 (MBL Interna-
tional), anti–derlin-2 (MBL International), and anti–calnexin-C (StressGen); 
and mouse monoclonal antibodies anti-ubiquilin (Invitrogen), anti-p97(VCP) 
(BD),  anti-Herp  (Abgent),  anti-Ufd1  (a  gift  of  H.  Meyer,  Swiss  Federal   
Institute of Technology, Zurich, Switzerland), anti-His (GE Healthcare), anti-
FLAG, anti-HA, anti-tubulin (all from Sigma-Aldrich), anti-ubiquitin (Santa 
Cruz Biotechnology, Inc.), and 6, 7, Rpt1, and Rpn10 subunits of the 
proteasome (all from Enzo Life Sciences, Inc.).
Cell fractionation and proteasome activity
HEK293 cells that were either treated with MG132 (50 nM final concentra-
tion) or left untreated were homogenized in 1 ml of buffer B (0.25 M su-
crose, 1 mM EDTA, and 10 mM Hepes-NaOH, pH 7.4) by 10 up-and-down 
strokes with the pestle using a Dounce homogenizer, then centrifuged at JCB • VOLUME 187 • NUMBER 2 • 2009   216
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cDNA cloned in the same vector was obtained from Thermo Fisher Scientific.   
The ubiquilin and erasin RNAi plasmids were transformed into Escherichia 
coli strain HT115 (DE3), and the resulting transformants were cultured over-
night at 37°C in Luria broth containing 50 µg/ml ampicillin and 12.5 µg/ml 
tetracycline. The cultures were diluted into fresh broth and grown to an 
OD600 of 0.5, after which IPTG was added to a final concentration of 0.4 mM 
and the incubation continued for another 2 h. The bacteria were then 
seeded onto nematode growth medium plates containing IPTG, and worms 
were added to the plates by chunking a piece of agar from a stock plate 
of the zcls4 strain of worms. The worms were allowed to feed for 24–36 h, 
after which they were collected and protein lysates were prepared and 
analyzed by immunoblotting (Wang et al., 2006).
Lifespan assay
Nematodes were synchronized by bleaching to obtain hermaphrodites in 
the fourth larval stage (L4). On day zero, L4 hermaphrodites were placed 
on individual 60-mm nematode growth medium agar plates containing   
2-deoxy-5-fluorouridine to prevent progeny growth and seeded with OP50   
E. coli bacteria or RNAi bacteria. Nematodes were grown for the duration 
of adult life at 20°C and were scored every 2 d. Animals were classified 
as dead if they failed to respond to a gentle tap on the head and tail with 
a platinum wire. Lifespan was defined as day zero to the day the worm 
was scored as dead. Statistical analysis software was used to compare 
mean lifespan of each treatment.
Online supplemental material
Fig. S1 shows in vitro binding assays mapping the ubiquilin-binding site in 
erasin. Fig. S2 shows GST pull-down assays to estimate the stoichiometry 
of erasin and p97/VCP binding in the trimeric complex. Fig. S3 shows the 
degree of colocalization of ubiquilin and erasin for Fig. 2 C and the co-
localization of calnexin with erasin and ubiquilin. Fig. S4 shows the bind-
ing affinity of ubiquilin and erasin determined from a Biacore experiment. 
Fig. S5 shows that JAMP, Herp, and Ufd1 do not coimmunoprecipitate 
with erasin. Online supplemental material is available at http://www.jcb 
.org/cgi/content/full/jcb.200903024/DC1.
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